Could the Novel Oral Anticoagulants Be Used for Coronary Artery Aneurysm?
| Autor: | Yu Jian, Libing Ning, Qinghua Yuan, Quanxiang Yan, Zhimin Du, Wencong Yang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Case Report 030204 cardiovascular system & hematology Angina 03 medical and health sciences 0302 clinical medicine Left coronary artery Aneurysm Internal medicine medicine.artery mental disorders medicine cardiovascular diseases 030212 general & internal medicine Myocardial infarction Coronary artery aneurysm Aspirin Rivaroxaban business.industry nutritional and metabolic diseases General Medicine medicine.disease medicine.anatomical_structure cardiovascular system Cardiology Medicine business Artery medicine.drug |
| Zdroj: | Case Reports in Medicine, Vol 2020 (2020) Case Reports in Medicine |
| ISSN: | 1687-9635 1687-9627 |
| DOI: | 10.1155/2020/5073814 |
| Popis: | Coronary artery aneurysms (CAAs) are uncommon in coronary angiography, and left main coronary artery aneurysms are rare. There is no consensus for the treatment of CAAs. A young patient with left coronary artery aneurysm diagnosed by coronary angiography and with recurrent acute myocardial infarction was treated with rivaroxaban and aspirin. The patient had no angina for 6 months. Novel oral anticoagulants combined with antiplatelet agents may be appropriate for the treatment of CAAs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|